Exact Mass: 485.1719
Exact Mass Matches: 485.1719
Found 435 metabolites which its exact mass value is equals to given mass value 485.1719
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ketotifen-N-glucuronide
Ketotifen-N-glucuronide is a metabolite of ketotifen. Ketotifen is a second-generation H1-antihistamine and mast cell stabilizer. It is most commonly sold in as a salt of fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks. Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds. (Wikipedia)
Fluoxetine glucuronide
Fluoxetine glucuronide is a metabolite of fluoxetine. Fluoxetine (also known by the tradenames Prozac, Sarafem, Fontex, among others) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Fluoxetine was first documented in 1974 by scientists from Eli Lilly and Company. It was presented to the U.S. Food and Drug Administration in February 1977, with Eli Lilly receiving final approval to market the drug in December 1987. Fluoxetine went off-patent in August 2001 (Wikipedia).
hydroxynefazodone
hydroxynefazodone is a metabolite of nefazodone. Nefazodone (Serzone, Nefadar) is an antidepressant marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries due to the rare incidence of hepatotoxicity (liver damage), which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in every 250,000 to 300,000 patient-years. On June 14, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States and Canada. (Wikipedia)
5-Biphenyl-4-yl-5-[4-(-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione
Afatinib
Amrubicinol (mixture)
Canertinib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Dibutyryl cyclic gmp
Erismodegib
p-Hydroxynefazodone
5-[4-(4-Nitrophenyl)piperazin-1-yl]-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
2-[3-[4-(3-Chlorophenyl)piperazin-1-yl]-1-hydroxypropyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
o2',o3',o5'-Tri-acetyl-n6-(3-hydroxyphenyl)adenosine
Vilanterol
beta-hydroxyorcein
A member of the class of phenoxazines that is 1,9-dimethyl-3H-phenoxazin-3-one carrying an additional hydroxy substituent at position 7 as well as two 2,4-dihydroxy-6-methylphenyl substituents at positions 2 and 8. The isomer in which the hydroxy groups at positions 2 and 2 on the phenyl rings are both on the same side of the plane of the phenoxazine ring system. A component of orcein, a mixture of dyes isolated from lichens.
3-carboxy-indole-10-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl ester|chaihuxinoside B
cypridina luciferin 3-enol sulfate|cypridina luciferin sulfate
Ala Cys His Arg
Ala Cys Arg His
Ala His Cys Arg
Ala His Met Gln
Ala His Gln Met
Ala His Arg Cys
Ala Met His Gln
Ala Met Gln His
Ala Gln His Met
Ala Gln Met His
Ala Arg Cys His
Ala Arg His Cys
Cys Ala His Arg
Cys Ala Arg His
Cys Cys Phe Asn
Cys Cys Asn Phe
Cys Phe Cys Asn
Cys Phe Asn Cys
Cys His Ala Arg
Cys His Ile Asn
Cys His Leu Asn
Cys His Asn Ile
Cys His Asn Leu
Cys His Gln Val
Cys His Arg Ala
Cys His Val Gln
Cys Ile His Asn
Cys Ile Asn His
Cys Leu His Asn
Cys Leu Asn His
Cys Asn Cys Phe
Cys Asn Phe Cys
Cys Asn His Ile
Cys Asn His Leu
Cys Asn Ile His
Cys Asn Leu His
Cys Asn Ser Tyr
Cys Asn Tyr Ser
Cys Gln His Val
Cys Gln Val His
Cys Arg Ala His
Cys Arg His Ala
Cys Ser Asn Tyr
Cys Ser Tyr Asn
Cys Val His Gln
Cys Val Gln His
Cys Tyr Asn Ser
Cys Tyr Ser Asn
Asp His Asn Thr
Asp His Gln Ser
Asp His Ser Gln
Asp His Thr Asn
Asp Asn His Thr
Asp Asn Thr His
Asp Gln His Ser
Asp Gln Ser His
Asp Ser His Gln
Asp Ser Gln His
Asp Thr His Asn
Asp Thr Asn His
Glu His Asn Ser
Glu His Ser Asn
Glu Asn His Ser
Glu Asn Ser His
Glu Ser His Asn
Glu Ser Asn His
Phe Cys Cys Asn
Phe Cys Asn Cys
Phe Asn Cys Cys
Gly His Ser Trp
Gly His Trp Ser
Gly Ser His Trp
Gly Ser Trp His
Gly Trp His Ser
Gly Trp Ser His
His Ala Cys Arg
His Ala Met Gln
His Ala Gln Met
His Ala Arg Cys
His Cys Ala Arg
His Cys Ile Asn
His Cys Leu Asn
His Cys Asn Ile
His Cys Asn Leu
His Cys Gln Val
His Cys Arg Ala
His Cys Val Gln
His Asp Asn Thr
His Asp Gln Ser
His Asp Ser Gln
His Asp Thr Asn
His Glu Asn Ser
His Glu Ser Asn
His Gly Ser Trp
His Gly Trp Ser
His Ile Cys Asn
His Ile Asn Cys
His Leu Cys Asn
His Leu Asn Cys
His Met Ala Gln
His Met Gln Ala
His Asn Cys Ile
His Asn Cys Leu
His Asn Asp Thr
His Asn Glu Ser
His Asn Ile Cys
His Asn Leu Cys
His Asn Ser Glu
His Asn Thr Asp
His Gln Ala Met
His Gln Cys Val
His Gln Asp Ser
His Gln Met Ala
His Gln Ser Asp
His Gln Val Cys
His Arg Ala Cys
His Arg Cys Ala
His Ser Asp Gln
His Ser Glu Asn
His Ser Gly Trp
His Ser Asn Glu
His Ser Gln Asp
His Ser Trp Gly
His Thr Asp Asn
His Thr Asn Asp
His Val Cys Gln
His Val Gln Cys
His Trp Gly Ser
His Trp Ser Gly
Ile Cys His Asn
Ile Cys Asn His
Ile His Cys Asn
Ile His Asn Cys
Ile Asn Cys His
Ile Asn His Cys
7-Hydroxyondansetron glucuronide
Leu Cys His Asn
Leu Cys Asn His
Leu His Cys Asn
Leu His Asn Cys
Leu Asn Cys His
Leu Asn His Cys
Met Ala His Gln
Met Ala Gln His
Met His Ala Gln
Met His Gln Ala
Met Gln Ala His
Met Gln His Ala
Asn Cys Cys Phe
Asn Cys Phe Cys
Asn Cys His Ile
Asn Cys His Leu
Asn Cys Ile His
Asn Cys Leu His
Asn Cys Ser Tyr
Asn Cys Tyr Ser
Asn Asp His Thr
Asn Asp Thr His
Asn Glu His Ser
Asn Glu Ser His
Asn Phe Cys Cys
Asn His Cys Ile
Asn His Cys Leu
Asn His Asp Thr
Asn His Glu Ser
Asn His Ile Cys
Asn His Leu Cys
Asn His Ser Glu
Asn His Thr Asp
Asn Ile Cys His
Asn Ile His Cys
Asn Leu Cys His
Asn Leu His Cys
Asn Ser Cys Tyr
Asn Ser Glu His
Asn Ser His Glu
Asn Ser Tyr Cys
Asn Thr Asp His
Asn Thr His Asp
Asn Tyr Cys Ser
Asn Tyr Ser Cys
Gln Ala His Met
Gln Ala Met His
Gln Cys His Val
Gln Cys Val His
Gln Asp His Ser
Gln Asp Ser His
Gln His Ala Met
Gln His Cys Val
Gln His Asp Ser
Gln His Met Ala
Gln His Ser Asp
Gln His Val Cys
Gln Met Ala His
Gln Met His Ala
Gln Ser Asp His
Gln Ser His Asp
Gln Val Cys His
Gln Val His Cys
Arg Ala Cys His
Arg Ala His Cys
Arg Cys Ala His
Arg Cys His Ala
Arg His Ala Cys
Arg His Cys Ala
Ser Cys Asn Tyr
Ser Cys Tyr Asn
Ser Asp His Gln
Ser Asp Gln His
Ser Glu His Asn
Ser Glu Asn His
Ser Gly His Trp
Ser Gly Trp His
Ser His Asp Gln
Ser His Glu Asn
Ser His Gly Trp
Ser His Asn Glu
Ser His Gln Asp
Ser His Trp Gly
Ser Asn Cys Tyr
Ser Asn Glu His
Ser Asn His Glu
Ser Asn Tyr Cys
Ser Gln Asp His
Ser Gln His Asp
Ser Trp Gly His
Ser Trp His Gly
Ser Tyr Cys Asn
Ser Tyr Asn Cys
Thr Asp His Asn
Thr Asp Asn His
Thr His Asp Asn
Thr His Asn Asp
Thr Asn Asp His
Thr Asn His Asp
Val Cys His Gln
Val Cys Gln His
Val His Cys Gln
Val His Gln Cys
Val Gln Cys His
Val Gln His Cys
Trp Gly His Ser
Trp Gly Ser His
Trp His Gly Ser
Trp His Ser Gly
Trp Ser Gly His
Trp Ser His Gly
Tyr Cys Asn Ser
Tyr Cys Ser Asn
Tyr Asn Cys Ser
Tyr Asn Ser Cys
Tyr Ser Cys Asn
Tyr Ser Asn Cys
1-deoxy-1-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]-b-D-Glucopyranuronic acid
Carbamic acid, N-[1-[4-(5-chloro-3-phenyl-1,6-naphthyridin-2-yl)phenyl]cyclobutyl]-, 1,1-dimethylethyl ester
Imiclopazine
C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent > C740 - Phenothiazine C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent
4-(2-[(6-Methoxy-3-pyridinyl)amino]-5-{[4-(methylsulfonyl)-1-pipe razinyl]methyl}-3-pyridinyl)-6-methyl-1,3,5-triazin-2-amine
afatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells[1]. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4].
Thieno[2,3-b]quinoline-2-carboxamide, N-[2-(cyclopentylamino)-2-oxoethyl]-7-methyl-N-[4-(1-methylethyl)phenyl]- (9CI)
N-[2-[4-[ethyl-[3-(methoxymethyl)pyridin-2-yl]amino]piperidine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
2,2-[[3-methyl-4-[(6-nitrobenzothiazol-2-yl)azo]phenyl]imino]bisethyl diacetate
N-[1,1-Biphenyl]-4-yl-9,9-diphenyl-9H-fluoren-2-amine
7,7-dimethyl-3-[(3-nitrophenyl)methyl]-1-(4-phenyl-1,3-thiazol-2-yl)-6,8-dihydroquinoline-2,5-dione
(1S,3S,5R,6R)-(4-nitrophenylmethyl)-1-dioxo-6-phenylacetamido-penam-3-carboxylate
Gemifloxacin mesylate
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic The mesylate salt of gemifloxacin. D004791 - Enzyme Inhibitors
Vilanterol
An organochlorine compound that is used in the form of its trifenate salt for treatment of chronic obstructive pulmonary disease. C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist Vilanterol (GW642444) is a long-acting β2-adrenoceptor (β2-AR) agonist with 24 h activity. The pEC50s for β2-AR,β1-AR and β3-AR is 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively.
Prucalopride Succinate
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D005765 - Gastrointestinal Agents > D054368 - Laxatives Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3][4].
N-(2,4-dimethoxyphenyl)-3-oxo-2-[[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]azo]butyramide
Sonidegib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XJ - Hedgehog pathway inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C188731 - Hedgehog Pathway Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3R)-tetrahydro-3-furanyloxy]-6-quinazolinyl}-4-(dimethylamino)-2-butenamide
N-([1,1-biphenyl]-3-yl)-9,9-diphenyl-9H-fluoren-amine
N-(4-(9-phenyl-9H-fluoren-9-yl)phenyl)-[1,1-biphenyl]-4-amine
Afabicin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic
4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)aMino)-1-hydroxyethyl)-2-(hydroxyMethyl)phenol
5-[4-(4-Nitrophenyl)piperazin-1-yl]-5-(4-phenylphenyl)-1,3-diazinane-2,4,6-trione
N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-Butenamide
(Z)-3-(1,3-benzothiazol-2-yl)-4-(3-methoxyphenyl)-N-(4-morpholinophenyl)but-3-enamide
gamma-Hydroxyorcein
A member of the class of phenoxazines that is 1,9-dimethyl-3H-phenoxazin-3-one carrying an additional hydroxy substituent at position 7 as well as two 2,4-dihydroxy-6-methylphenyl substituents at positions 2 and 8. The isomer in which the hydroxy groups at positions 2 and 2 on the phenyl rings are situated on opposite sides of the plane of the phenoxazine ring system. A component of orcein, a mixture of dyes isolated from lichens.
N-[1-(Aminomethyl)cyclopropyl]-3-(benzylsulfonyl)-N~2~-[(1S)-2,2,2-trifluoro-1-(4-hydroxyphenyl)ethyl]-L-alaninamide
[(2R,3S,4S)-5-[8-(dimethylamino)-7-methyl-2,4-dioxobenzo[g]pteridin-10-yl]-2,3,4-trihydroxypentyl] dihydrogen phosphate
[4-[2-(butanoylamino)-6-oxo-1H-purin-9-yl]-2-hydroxy-2-oxo-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-6-yl]methyl butanoate
N-[2-[(cyclohexylamino)-oxomethyl]phenyl]-4-methyl-3-(4-morpholinylsulfonyl)benzamide
3-[(E)-{2-[4-(morpholin-4-yl)-6-(phenylamino)-1,3,5-triazin-2-yl]hydrazinylidene}methyl]phenyl furan-2-carboxylate
N-[5-(diethylsulfamoyl)-2-(4-morpholinyl)phenyl]-2-oxo-1-benzopyran-3-carboxamide
2-[[4-amino-5-(3,4-dimethoxyphenyl)-1,2,4-triazol-3-yl]thio]-1-(1H-indol-3-yl)-2-phenylethanone
4-amino-N5-[1-(2-furanyl)-2-(3-methylbutylamino)-2-oxoethyl]-N5-(2-methoxyphenyl)isothiazole-3,5-dicarboxamide
(2S,4S)-4-(1-benzothiophen-3-yl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-N-(phenylmethyl)-3,4-dihydro-2H-pyran-6-carboxamide
4-[[(4-acetyl-2,3-dihydro-1,4-benzoxazin-7-yl)sulfonylamino]methyl]-N-(3-methylphenyl)-1-cyclohexanecarboxamide
butanoic acid [(4aS,7S,7aS)-2-hydroxy-2-oxo-6-[6-oxo-2-(1-oxobutylamino)-3H-purin-9-yl]-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphorin-7-yl] ester
(2S,3S,4S,5R)-6-[2-cyano-2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
3-(p-carboxyphenylazo)-N-acetyl-L-tyrosylglycylglycine
1-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-(2-morpholin-4-yl-2-oxoethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-(2-morpholin-4-yl-2-oxoethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-(2-morpholin-4-yl-2-oxoethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-3-(2-fluorophenyl)urea
3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
2-[(2R,4aS,12aS)-8-[(2-methoxy-1-oxoethyl)amino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(4-fluorophenyl)acetamide
(3R,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
1-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-(2-morpholin-4-yl-2-oxoethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(2-fluorophenyl)urea
3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-(1-methylimidazol-4-yl)sulfonylamino]butyl]urea
3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-(1-methylimidazol-4-yl)sulfonylamino]butyl]urea
(3S,6aR,8S,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
N-[(4S,7S,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7S,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7R,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7R,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2R,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2R,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
3,5-dichloro-N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
1-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
2-[(2S,4aS,12aR)-5-methyl-6-oxo-8-[(1-oxo-2-thiophen-2-ylethyl)amino]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-propylacetamide
(3S,6aS,8R,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(2S,3S,3aR,9bR)-N-[(2-chlorophenyl)methyl]-3-(hydroxymethyl)-1-[4-oxanyl(oxo)methyl]-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
[(1S)-7-methoxy-9-methyl-2-methylsulfonyl-1-(5-pyrimidinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1R)-7-methoxy-2-(3-methoxyphenyl)sulfonyl-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(2-pyrazinyl)methanone
N-[(4R,7R,8S)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4S,7S,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(4R,7R,8R)-8-methoxy-5-(2-methoxy-1-oxoethyl)-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
N-[(2S,3R,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3R,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6S)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
N-[(2S,3S,6R)-6-[2-[(3,4-dichlorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(1-piperidinyl)propanamide
3,5-dichloro-N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
3,5-dichloro-N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[1-oxo-3-(1-piperidinyl)propyl]amino]-2-oxanyl]ethyl]benzamide
1-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(2-fluorophenyl)urea
1-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
1-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-3-[2-(4-morpholinyl)-2-oxoethyl]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-3-(4-fluorophenyl)urea
2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[[(4-methoxyanilino)-oxomethyl]amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-methoxyethyl)acetamide
3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl-[(1-methyl-4-imidazolyl)sulfonyl]amino]butyl]urea
(3R,6aS,8R,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8R,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8S,10aS)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8S,10aR)-8-[2-(cyclobutylamino)-2-oxoethyl]-N-(3,4-dichlorophenyl)-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3aR,4S,9bS)-8-[2-(3-fluorophenyl)ethynyl]-4-(hydroxymethyl)-N-(2-methoxyphenyl)-5-methyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[3,2-c]quinoline-1-carboxamide
[(1S)-7-methoxy-2-(3-methoxyphenyl)sulfonyl-1-methyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-2-(cyclopropylmethyl)-7-methoxy-9-methyl-1-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-2-(cyclopropylmethyl)-7-methoxy-9-methyl-1-[(1-methyl-4-imidazolyl)sulfonyl]-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol
[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(2-pyrazinyl)methanone
1-(2-methoxyphenyl)-3-[(E)-(1-methyl-5-piperidin-1-ylsulfonylindol-3-yl)methylideneamino]thiourea
2-amino-4-({2-[(1-carboxy-2-hydroxy-1-methyl-2-phenylethyl)sulfanyl]-1-[(carboxymethyl)-C-hydroxycarbonimidoyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxy-4-methoxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
4,7-DI(4-Methoxyphenyl)-6-(3,4-dimethoxyphenyl)-1,2.5-thiadiazolo(3,4-C)pyridine
(2E,5E)-5-benzyl-6-chloro-2-methyl-N-[3-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]butan-2-yl]hexa-2,5-dienamide
Canertinib
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
Fluoxetine glucuronide
IMM-H007
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3]. IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis[1][2][3].